Between January and May 2019, Russia produced 157.5 bln RUB worth of pharmaceutical drugs (manufacturers’ dispatch prices, VAT included), which is in monetary terms (rubles) 19.1% higher than that of the same period in 2018. While the dynamics are positive, they are still significantly lower than those of 2018. These dynamics are due to May’s negative dynamics in monetary terms and low positive in physical terms.

For the Russian pharmaceutical retail, the first months of 2019 were highlighted by a significant growth of the market volume in monetary terms (+6.1% in rubles) against last year’s stagnation. The high dynamics are mostly due to a surge in influenza and ARVI incidence, with the epidemiological season being rather atypical both in terms and incidence rates. The pharmaceutical inflation rates, which reached 5.6% from January to March, also contributed to the dynamics. At the same time, incomes of the population for the period have fallen by an impressive 2.3%. Russians began to actively save money, which this is not just a hypothesis; the trends of “savings behavior” are confirmed by the surveys of such organizations as VTsIOM (Russian Public Opinion Research Center) and research holding Romir.

Between January and March 2019, Russia imported 14.2 bln RUB worth of veterinary products (free circulation prices), which is in monetary terms (rubles) 1.8% higher than that of the same period in 2018. The dynamics of the import of veterinary drugs are +10% (6.2 bln RUB), which is the highest dynamics among the three groups. The lowest import dynamics belong to feed supplements, with -4.5% (7.5 bln RUB). The dynamics of the API import in monetary terms are +8.3%, with 529 bln RUB.

Between January and March 2019, Russia imported 25.4 bln RUB worth of APIs (free circulation prices, VAT included), which is in monetary terms (rubles) 15.4% higher than that of the same period in 2018. The dynamics is physical terms are -1.6% (in tons), with 2.6 thousand tons.

Between January and March 2019, Russia imported 125.5 bln RUB worth of ready-made pharmaceutical drugs (free circulation prices), which is in monetary terms (rubles) 8.5% higher than that of the same period in 2018, and 30 bln RUB worth of in-bulk drugs, which is in monetary terms 24.4% higher than that of the same period in 2018. The total dynamics are +11.3% for the period.

Between January and April 2019, Russia produced 127.4 bln RUB worth of pharmaceutical drugs (dispatch prices, VAT included), which is in monetary terms (rubles) 26.3% higher than that of the same period in 2018. These high dynamics are due not only to inflation but also to high production volume in physical terms (+4.1%).

Earlier this year, the market saw a renewed growth in monetary terms and the long forgotten double-digit, which looks very impressive in contrast with the moderate results of 2018. However, the dynamics were mostly achieved by the state segment due to the events far from unexpected or inexplicable in the industry. As for retail, the dynamics were just beyond the inflation rates, while the actual demand continues to drop, which is logical due to income decline of the population.

Between January and April 2019, Russia imported over 3.6 bln RUB worth of pharmaceutical drugs made in the EEU countries (wholesale prices, VAT included), which is in monetary terms (rubles) 37.8% higher than that of the same period in 2018. In physical terms (units), the dynamics are +46.3%, with 85.4 mln units of pharmaceuticals.

Between January and March 2019, Russia imported 2.6 bln RUB worth of pharmaceuticals made in the EEU countries (wholesale prices, VAT included), which is in monetary terms 49.6% higher than that of the same period in 2018. The dynamics in physical terms are +61.2% (65.3 mln units).

Between January and March 2019, Russia produced 86.9 bln RUB worth of pharmaceuticals (manufactures’ dispatch prices, VAT included), which is in monetary terms 14.7% higher than that of the same period of 2018. However, the dynamics in physical terms are only +0.5% (1.01 bln units).